The purpose of stem cell therapy for myocardial infarction is to improve clinical outcomes, and detailed information on clinical outcomes is critical to appropriate planning of phase III trials. We have examined data from select phase II trials using autologous bone-marrow-derived stem cells in patients with acute myocardial infarction. We have extracted available definitions and outcome data, and have generated standardized estimates of events to permit summary comparisons. Nine trials (1,040 patients) with results for 6 months to 5 years were evaluated. Adverse outcomes differed widely, and there was a general lack of details in the definitions of these outcomes. Heart-failure-related hospitalizations occurred in only 16 patients (1.5 %) and death occurred in only 43 patients (4.1 %). Ischemiarelated outcomes outnumbered heart failure outcomes more than tenfold. Uniform criteria need to be developed to better define clinical outcomes of interest. Furthermore, a refocus from heart failure outcomes to ischemia-related outcomes seems appropriate.
Introduction
In recent years, stem cell therapy to improve left ventricular (LV) function after acute myocardial infarction (MI) has become an area of increasing interest. But much additional investigation is required if cell therapy is to become an effective treatment strategy aimed at improving clinical outcomes. Indeed, most of the focus to date has been directed toward effects on LV function, perfusion, and cell fate in this ischemic population [1, 2•, 3, 4, 5•, 6•, 7, 8•, 9, 10•, 11, 12, 13, 14•, 15, 16, 17, 18, 19, 20•, 21, 22•, 23] . However, the goal is not just the demonstration of increased LV function, but also to decrease adverse outcomes in this atrisk, post-MI population. Additionally, the literature suggests that information on objective clinical outcomes such as death, MI, arrhythmias, and hospitalization for heart failure and other cardiac reasons has not been emphasized [1, 2•, 3, 4, 5•, 6•, 7, 8•, 9, 10•, 11, 12, 13, 14•, 15, 16, 17, 18, 19, 20•, 21, 22•, 23] . The investigation of cell therapy has been confined to phase I and early phase II studies, as required for evaluation of new procedures for which the safety profile is unknown. Because little is known about possible risks and benefits, these trials include relatively small numbers of patients. Yet information about clinical events is critical to adequately design appropriately powered phase III trials.
The purpose of this article is to critically examine and summarize reported phase II clinical trial results with respect to secondary clinical outcomes. Specific focus will be placed on the definitions used, as well as the incidence of these clinical outcomes in order to better design future trials assessing the influence of cell-based therapy on clinical adverse outcomes.
Methods
We conducted a search of the English literature for randomized trials that used autologous bone-marrow-derived stem cells (BMCs) in patients with acute MI. To ensure sufficient research team experience, we limited the search to trials reporting 50 or more patients with clinical outcomes after at least 6 months of follow-up. Additional selection criteria included BMCs delivered into an infarct-related artery after reperfusion by percutaneous intervention. For trials with multiple reports, we used only the report with the longest follow-up duration that contained clinical outcome data. We extracted the reported definitions for each event when this information was provided and tabulated the reported event rates. Event rates are recorded per patient, and patients with multiple events in a single category were recorded only once (Table 1) .
To account for differences in trial follow-up duration, we generated standardized estimates of event rates to permit comparison of event rates for the different clinical outcomes across all trials. By employing a weighted general linear model, using the cumulative total of the study sample as the standard population, we estimated the event rates per year per 1,000 for each outcome among the cell intervention and control groups for each study identified. Standardized event rates were calculated for death, MI, coronary artery bypass graft, overall coronary revascularization, target vessel revascularization (TVR), and heart failure hospitalizations as the clinical outcomes of most interest (Table 2) .
Results
From a total of 33 trials identified, ten met the preset criteria summarized in the previous section (Fig. 1 ). One trial (66 patients) was excluded since patients were not followed after early events that influenced LV function. A total of nine randomized controlled phase II trials [1, 2•, 3, 4, 5•, 6•, 7, 8•, 9, 10•, 11, 12, 13, 14•, 15, 16, 17, 18, 19, 20•, 22•, 23] published from 2002 to the present were identified, and included 1,040 patients with more than 275 clinical events (Table 1) . A tenth trial published in 2008 [21] comprised 66 patients randomized to control, high-dose BMC, and lowdose BMC groups. This trial excluded patients once they experienced any event that affected LV function, and thus we did not include this trial in our analysis. In a 2012 Cochrane Review [24•] , most of the trials listed did not meet our selection criteria. In the remaining nine trials, we found that the definitions and numbers of events reported differed greatly across the trials, and the primary measures of interest centered on LV function, size, perfusion, and infarct size in this post-MI population. Although definitions of the primary outcome measures were clearly stated, only limited information was provided to define the clinical outcomes reported. Some trials also reported the numbers of patients experiencing a "first event" among a cluster of events (Table 3) . A complete summary of each trial's clinical outcomes and definitions of these outcomes is given in the Appendix.
Overall, a total of 1,040 patients were described from these nine trials, and the patients were followed for up to 5 years in some of the trials. The major clinical events of each trial are reported in Table 1 . In total, 43 patients died, 22 had an MI, and another five had a stroke. Repeat revascularization procedures were performed in 179 patients: 127 TVRs, 33 non-TVRs, six coronary artery bypass graft surgical procedures, and 24 unspecified revascularizations were performed. A total of 16 patients were hospitalized for heart failure reasons, and 15 patients had ventricular arrhythmias. Cancers were detected in six patients, but in some cases the authors commented that evidence for cancer predated the cell-based treatments. Unfortunately, very few of these nine trials commented on specific prospective criteria for these clinical events. Over half of the trials (ASTAMI [9] , FINCELL [8•] , BALANCE [20•] , REGENT [18] , and LateTIME [22•]) provided no definitions for the clinical events they reported, accounting for 109 (47 %) of the 233 definable events (death needing no definition) reported by all nine studies. Two trials [6•, 10•, 11, 19] defined in-stent restenosis, and one trial [1, 3, 14 •] defined recurrent MI (see the Appendix). These three trials otherwise provided no definitions of their clinical outcomes, accounting for another 32 of the reported clinical events that were not defined. REPAIR-AMI [2•, 7, 15, 16, 17, 23] provided the most complete account of its clinical outcomes, defining recurrent MI, rehospitalization for congestive heart failure, ventricular arrhythmia, syncope, cerebrovascular accident, and cancer (see the Appendix). Of the 90 definable events reported by REPAIR-AMI, 74 were not defined [2•, 7, 15, 16, 17, 23] . Thus, in total 215 (92 %) of the 233 definable events reported in Table 1 were not defined.
Although all of these trials mentioned heart failure prevention in the post-MI patient with LV dysfunction as the primary rationale for treatment, we observed that hospitalization for heart failure reasons occurred infrequently (in 16 of 1,040 patients, or only 1.5 %). When standardized per 1,000 patients, heart failure hospitalizations occurred in 5.3 per 1,000 controls and in only 1.9 per 1,000 BMC patients. Not surprisingly, repeat revascularization procedures were the most frequent events, occurring in 17 % of patients treated (179 of 1,040 patients). When standardized per 1,000 patients, total repeat revascularizations were similar in both groups, occurring in 27.1 per 1,000 controls and 27.5 per 1,000 BMC patients. There were fewer TVRs in the BMC group, 12.7 per 1,000 versus 16.6 per 1,000 in the controls. The standardized event rates per 1,000 for MI and death were also lower in the BMC group (Table 2) . Thus, even though BMCs did not affect the overall need for revascularization, they may have had an impact on the most important events: TVR, MI, and death. When compared with a similar population of acute coronary syndrome patients with a 5-year follow-up (GRACE UKBelgian Study [25] ), the death rate was significantly lower in the BMC group (43/1,040, or 4.1 %, over 5 years) than in the GRACE UK-Belgian Study (736/3,721, or 19.7 %, over 5-years). Similarly, the incidence of MI was significantly lower than in the UK cohort (22/1,040, or 2.1 %, over 5 years vs 320/2,065, or 15.4 %, over 5 years) [25] . Of course, it is difficult to compare ischemic events between these trials because there are several variables that are not uniform, including the time to percutaneous coronary intervention (PCI) and the type of stent used (drug-eluting stent vs bare metal stent). Nonetheless, these findings suggest that more emphasis should be placed on defining, in a uniform fashion, the outcomes that are likely ischemia-related. To this end, the criteria used for recurrent MI could be critical as well as those used for repeat revascularization. Given the importance of defining recurrent B bone-marrow-derived stem cell group, C control group, CABG coronary artery bypass graft, CHF congestive heart failure, CVA cerebrovascular accident, MI, myocardial infarction, TVR target vessel revascularization, x not reported on in the study a Five-year data are reported for death, and the remaining data are from the 2-year data b Selected and unselected bone-marrow-derived stem cell (BMC) groups are combined c The circulating progenitor cell group was the control group. A total of 16 TVRs were reported at 5 years [1••], but the numbers for the control and BMC groups were not specified. The data in the table are from the 1-year follow-up BMC bone-marrow-derived stem cell group, CABG, coronary artery bypass graft, CHF, congestive heart failure, MI myocardial infarction, TVR target vessel revascularization, x not reported on in the study Heart Association/World Heart Federation expert consensus document [26] for recurrent MI after PCI should be used. Recurrent MI is defined as an increase in troponin T level more than three times the 99th percentile of the upper limit of normal. Similarly, the standard of 50 % or more narrowing of the luminal diameter should be used as the definition for in-stent restenosis [27] .
Discussion
As expected with all early-phase clinical studies primarily focused on safety and feasibility, clinical outcomes and efficacy measures were secondary interests in these initial cardiovascular cell therapy clinical trials. In all nine trials identified in our search for further examination, a clinical surrogate, in most cases LV ejection fraction (LVEF), was the primary measure of interest. This is interesting, given the fact that these trials were conducted in acute MI patients and a marker such as need for repeat revascularization or recurrent MI would seem more appropriate. Clinical outcomes were relatively infrequent in these small studies, and their low occurrence rate all but ensured that enough clinical events would not have occurred for precise and reliable detection of a treatment effect generalizable to the population. For example, a clinical trial with a single treatment arm and control group arm requires as many as 3,300 patients in order to detect a 20 % reduction in the event rate if the control group event rate is 18 % (with a two-sided type I error level of 0.05 and 80 % power). Therefore, in a standard analysis setting, phase II clinical trials are relegated to measuring clinical end points as secondary outcomes, where they can at least provide some useful information about how best to design future phase III trials. The primary end points of these trials focused on LV function and heart failure in this acute MI population. Surprisingly, the incidence of hospitalization for congestive heart failure was low (1.5 %) across all of the trials. One explanation for this could be that this was an acute MI population of patients who presumably had normal LV function prior to their acute MI, and who were revascularized quickly, thus decreasing the incidence of lasting LV dysfunction. The data suggest a trend of decreased hospitalization rates for heart failure in the BMC group (1.9/1,000 vs 5.3/1,000 in the control group). The difference between the groups is 3.4 patients per 1,000, and thus is not likely significant. The overall need for repeat revascularization between the BMC and control groups was similar, but the incidences of TVR, MI, and death were all lower in the BMC group, indicating an effect on ischemia-related outcomes.
Several recommendations can be made to the scientific community for the design of studies to examine these secondary B bone-marrow-derived stem cell group, C control group, CHF congestive heart failure, MI myocardial infarction, TVR target vessel revascularization, x not reported on in the study a The circulating progenitor cell group was the control group clinical outcomes. First, uniform criteria should be developed to better define the clinical outcomes of interest in these trials. We must understand how treatment may influence these outcomes and thus provide direction for the design of future trials. For example, if a cell therapy graft is designed to revascularize myocardial tissue, then efficacy outcome measures should focus on quantifying myocardial perfusion and clinical outcomes related to improved perfusion (e.g., fewer ischemia-related events). Second, prospective study designs such as cohort and experimental studies can illuminate the incidence of these events in a target population. It is important to know the incidence of these events in a population to determine sample size estimates for future studies. In addition, in the design of phase I/II clinical trials, targeting a population that is at high risk of these outcomes would provide the incidence rates (and power) necessary to adequately examine these events. For example, if MI were one of the events of interest, targeting a population at high risk of developing MI such as those with unstable angina would provide the necessary sample size to examine these outcomes of interest [28, 29••] .
Limitations
This is a retrospective analysis of previously published BMC trials that were neither designed nor powered to focus on secondary clinical outcomes. Nevertheless, the events comprising these outcomes, and their frequencies, are critically important for proper planning of more definitive trials. The event rates observed may have been influenced by the design of each of the trials. Also, the time to initial revascularization, the type of revascularization (bare metal stent vs drugeluting stent), the time to injection of BMCs, and the type of BMCs used differed greatly among the studies. Each of these variables may have influenced the capture of the secondary outcomes reported, thus limiting any statistical analysis of these events.
Conclusion
In summary, even with the aforementioned limitations, there appears to be an increased incidence of ischemia-related events compared with heart failure events in this population over the intermediate-term follow-up. These findings suggest the need to focus on ischemia-related outcomes in future cell therapy trials. The purpose of this investigation was to examine the criteria used for these clinical outcomes in phase II trials; it is clear that there is a need for standard definitions of these outcomes in order to better design future phase III trials.
function, and LV diastolic function [4] . They did report a statistically significant increase in exercise time at 2-3 weeks and at 3 years in the BMC group, but no difference in peak oxygen consumption [5•] . Their 3-year reported clinical outcomes are noted in Table 1 . In addition to the outcomes reported in Table 1 , they also reported three episodes of sustained ventricular arrhythmias and no detected cancers. None of the clinical outcomes were defined [5•] . FINCELL [8•] randomized 80 patients to BMC (40 patients) and control (40 patients) groups after thrombolytic therapy prior to PCI. The investigators reported in their 6-month data that the absolute change in global ejection fraction measured by both LV angiography and echocardiogram was significantly greater in the BMC group when compared with controls. No significant differences were found between the control group and the BMC group with regard to intravascular ultrasound measurements or arrhythmia risk variables [8•] . They reported several clinical outcomes as well (Table 1 ). Prior to initial hospital discharge, one episode of no reflow in the infarct-related artery after PCI occurred in the BMC group. There were four episodes of major bleeding-one episode in the BMC group and three episodes in the control group. Major bleeding was not defined. They also reported four episodes of subacute stent thrombosis prior to hospital discharge-one episode in the BMC group and three episodes in the control group [8•] . None of these clinical end points were defined.
The FINCELL investigators reported two additional substudies on inflammatory markers and their relation to LVEF [12, 13] . They first looked at the relationship between baseline LVEF and baseline levels of inflammatory markers, including NT-proBNP [12] . They found that patients in the BMC group who had an initial LVEF below the median (62.5 % or less) had a significantly greater improvement in LVEF at 6 months when compared with the control group or those patients in the BMC group with an LVEF above the median. They also found a significant correlation between baseline NT-proBNP levels and improvement in 6-month LVEF in the BMC group [12] . Unfortunately, in a second substudy they found an overall decline in NT-proBNP levels from the baseline to 6 months, but there was no statistical difference between the BMC group and the control group. They also found no statistically significant differences in the levels of N-terminal atrial natriuretic peptide prohormone, interleukin-6, high-resolution C-reactive protein, or tumor necrosis factor α between the BMC group and the control group at 6 months [13] .
BALANCE [20•] randomized 124 patients to BMC (62 patients) and control (62 patients) groups. The investigators reported improvements in LVEF, LV volumes, and contractility in their 5-year data. They commented on a limited number of clinical outcomes (Table 1) . In addition to the data shown in Table 1 , they reported no statistical difference in unplanned hospitalizations (14.5 in the BMC group, 12.9 in the control group). They also reported a statistical difference in mortality favoring the BMC group [20•] . No clinical outcomes were defined.
Cao et al. [6• ] randomized a total of 86 patients to receive BMCs (41 patients) or to a control group (45 patients). They reported 4-year follow-up data which noted statistically significant improvements in LVEF, LV end-systolic volume, and LV wall motion index at 6 months, 1 year, and 4 years when compared with controls [6•] . A limited amount of data on clinical outcomes were reported (Table 1) . In addition to the data shown in Table 1 , one case of "transient heart failure" occurred in the BMC group. They reported no arrhythmias, cancers, or intramyocardial calcifications [6•] . Instent restenosis was defined as more than 50 % loss of luminal diameter within a stent. Other than this, no other clinical outcomes were defined.
BOOST [10•, 11, 19] randomized 100 patients to either a BMC group (50 patients) or a control group (50 patients). Although there were early differences, no significant difference in LVEF between the BMC and control groups at 5 years was observed. However, in a substudy analysis, patients in the BMC group who experienced a transmural infarct greater than the median did show a statistically significant improvement in LVEF at 5 years when compared with those patients with a transmural infarct less than the median [10•] . Several clinical outcomes were reported in their 5-year follow-up (Table 1 ). In addition to the information noted in Table 1 , they also reported two cases of either ventricular tachycardia or syncope, one in each group. The distinction between ventricular tachycardia and syncope was not made. One case of cancer was detected in the control group as well. New York Heart Association class was also commented on, with no statistical significance between the groups. The BOOST investigators also commented on one composite outcome (Table 2 ). They defined in-stent restenosis as at least 50 % narrowing of the luminal diameter a10••]. No other clinical outcomes were defined.
REGENT [18] enrolled 200 patients to receive either selected BMCs (80 patients) or unselected BMCs (80 patients) or into a control group (40 patients). Six-month follow-up data revealed no statistically significant improvements in LVEF or LV volumes measured by MRI between the BMC and control groups. Four clinical outcomes were reported in this study (Table 1) . No clinical outcomes were defined.
REPAIR-AMI [2•, 7, 15, 16, 17, 23] randomized 204 patients to a BMC group (101 patients) or a control group (103 patients). The investigators reported at 1 year a significant decrease in the occurrence of death, recurrent MI, or need for revascularization. They also found a decrease in the occurrence of death, recurrent MI, or rehospitalization for heart failure [16, 17] . The 2-year follow-up MRI data revealed significant improvements in relative infarct size and regional contractility [2•, 7] . A substudy analysis also reported improvement in LVremodeling parameters at 4 months in the BMC group that were not present in the control group [15] . These investigators reported other numerous clinical outcomes as well in their 2-year data (Table 1) and provided the most complete definitions of their clinical data. They reported a statistically significant difference in the occurrence of MI between the BMC group and the control group. Recurrent MI was defined as a creatinine kinase level two times the upper limit of normal with a significant (more than 6 %) MB fraction or new Q waves on the electrocardiogram (ECG). There was no significant difference in the rates of rehospitalization for heart failure between the groups. Rehospitalization for heart failure was defined as hospitalization with clinical findings of heart failure requiring medication adjustment. There were no significant differences in the need for TVR between the groups. The criteria for revascularization were not defined. There were a total of ten patients with ventricular arrhythmias-five in the control group and five in the BMC group. Ventricular arrhythmia was defined as any ventricular tachycardia or ventricular fibrillation on ECG, ambulatory ECG monitor, or pacemaker/implantable cardioverter defibrillator interrogation. Only two syncopal events occurred, both in the control group. Syncope was defined as any self-limiting or transient loss of consciousness. There was no statistical difference in the rate of strokes between the groups. Stroke was defined as any focal neurological deficit persisting for more than 24 h, and was confirmed by a neurologist or imaging study. Finally, four cancers were reported-three in the control group and one in the BMC group. Cancer was defined as any new or recurrent disease confirmed by histology [2•, 7, 15, 16, 17, 23] . Five-year follow-up data were presented at the 2011 Madrid cell therapy meetings. At that time, in the placebo group, death had occurred in 15 patients (of which eight were cardiac deaths and three were sudden cardiac deaths). Among the BMC group, death occurred in seven patients (of which four were cardiac deaths and three were sudden cardiac deaths). The investigators also reported no significant differences in the incidence of syncope and ventricular arrhythmia, with seven instances in the placebo group and six in the BMC group; no distinction was made between ventricular arrhythmia and syncope. The incidence of cancer was similar, with seven occurrences in the placebo group and four in the BMC group. From these 5-year data, only the data on death are included in the analysis in this article. The remaining data are from the 2-year report.
The REPAIR-AMI investigators also commented on four different combined outcomes (Table 2) . They reported a statistically significant difference in the combined outcomes of death or MI, death, MI, or any revascularization, and death, MI, or rehospitalization for heart failure, all favoring the BMC group. They reported no difference for the outcome of death, MI, or infarct vessel revascularization [2•, 17] . LateTIME [22• ] randomized 87 patients with anterior MI 2-3 weeks previously and who had an LVEF of 45 % or less to a BMC group (58 patients) or a control group (29 patients). The primary outcomes were global and regional LVEF measured by cardiac MRI. The 6-month follow-up data revealed no statistical significance in global or regional LVEF between the placebo and BMC groups. None of these clinical outcomes were defined.
